MarzulloRAprileAClementiF. Paclitaxel eluting balloon: from
bench to bedside. Minerva Cardioangiol.
2009;57:597–609.
2.
SchellerBHehrleinCBockschW. Treatment of coronary in-stent
restenosis with a paclitaxel-coated balloon catheter.
N Engl J Med.
2006;355:2113–2124.
3.
SchellerBCleverYPKelschB. Long-term follow-up after treatment
of coronary in-stent restenosis with a paclitaxel-coated balloon
catheter. JACC Cardiovasc Interv.
2012;5:323–330.
4.
KleberFXMatheyDGRittgerH. How to use the drug-eluting balloon:
recommendations by the German consensus group.
EuroIntervention. 2011;7Suppl K:K125–128.
5.
RittgerHBrachmannJSinhaAM. A randomized, multicenter,
single-blinded trial comparing paclitaxel-coated balloon angioplasty with
plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES
study. J Am Coll Cardiol.
2012;59:1377–1382.
6.
Task Force on Myocardial Revascularization
of the European Society of Cardiology (ESC) and the European Association for
Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous
Cardiovascular Interventions (EAPCI), WijnsWKolhPDanchinN. Guidelines on myocardial
revascularization. Eur Heart J.
2010;31:2501–2555.
7.
TepeGZellerTAlbrechtT. Local delivery of paclitaxel to
inhibit restenosis during angioplasty of the leg. N
Engl J Med.
2008;358:689–699.
8.
WerkMLangnerSReinkensmeierB. Inhibition of restenosis in
femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral
paclitaxel randomized pilot trial.
Circulation.
2008;118:1358–1365.
9.
FanelliFCannavaleABoattaE. Lower limb multilevel treatment with
drug-eluting balloons: 6-month results from the DEBELLUM randomized
trial. J Endovasc Ther.
2012;19:571–580.
10.
VajdaZGütheTPerezMA. Neurovascular in-stent stenoses:
treatment with conventional and drug-eluting balloons.
AJNR Am J Neuroradiol.
2011;32:1942–1947.
MontorsiRGalliSRavagnaniRM. Drug-eluting balloon for treatment of
in-stent restenosis after carotid artery stenting: preliminary
report. J Endovasc Ther.
2012;19:734–742.
13.
TekieliLPieniazekPMusialekP. Zotarolimus-eluting stent for the
treatment of recurrent, severe carotid artery in-stent stenosis in the
TARGET-CAS population. J Endovasc Ther.
2012;19:316–24.
14.
ZhouWLinPHBushRL. Management of in-stent restenosis
after carotid artery stenting in high-risk patients.
J Vasc Surg.
2006;43:305–312.
15.
ReichmannBLvan LaanenJHde VriesJP. Carotid endarterectomy for treatment
of in-stent restenosis after carotid angioplasty and
stenting. J Vasc Surg.
2011;54:87–92.
16.
JostDUnmuthSJMeissnerH. Surgical treatment of carotid
in-stent-restenosis: novel strategy and current management.
Thorac Cardiovasc Surg. 2012 Jul 12. [Epub
ahead of print]
17.
van
HaaftenACBotsMLMollFL. Therapeutic options for carotid
in-stent restenosis: review of the literature. J
Vasc Interv Radiol.
2010;21:1471–1477.
18.
HerdegCOberhoffMBaumbachA. Local paclitaxel delivery for the
prevention of restenosis: biological effects and efficacy in
vivo. J Am Coll Cardiol.
2000;35:1969–1976.
19.
PósaANyolczasNHemetsbergerR. Optimization of drug-eluting balloon
use for safety and efficacy: evaluation of the 2nd generation
paclitaxel-eluting DIOR-balloon in porcine coronary
arteries. Catheter Cardiovasc Interv.
2010;76:395–403.
20.
CremersBSpeckUKaufelsN. Drug-eluting balloon: very short-term
exposure and overlapping. Thromb Haemost.
2009;101:201–206.
21.
RadkePWJonerMJoostA. Vascular effects of paclitaxel
following drug-eluting balloon angioplasty in a porcine coronary model: the
importance of excipients. EuroIntervention.
2011;7:730–737.
22.
StellaPRBelkacemiAWaksmanR. The Valentines Trial: results of the
first one week worldwide multicentre enrolment trial, evaluating the real
world usage of the second generation DIOR paclitaxel drug-eluting balloon
for in-stent restenosis treatment.
EuroIntervention.
2011;7:705–710.
23.
BelkacemiAAgostoniPNathoeHM. First results of the DEB-AMI (drug
eluting balloon in acute ST-segment elevation myocardial infarction) trial:
a multicenter randomized comparison of drug-eluting balloon plus bare-metal
stent versus bare-metal stent versus drug-eluting stent in primary
percutaneous coronary intervention with 6-month angio-graphic,
intravascular, functional, and clinical outcomes. J
Am Coll Cardiol.
2012;59:2327–2337.
24.
StellaPRBelkacemiADuboisC. A multicenter randomized comparison
of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus
drug-eluting stent in bifurcation lesions treated with a single-stenting
technique: six-month angiographic and 12-month clinical results of the
drug-eluting balloon in bifurcations trial. Catheter
Cardiovasc Interv. 2012 Mar 15 [Epub ahead of
print]
25.
RittgerHBrachmannJSinhaAM. A randomized, multicenter,
single-blinded trial comparing paclitaxel-coated balloon angioplasty with
plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES
study. J Am Coll Cardiol.
2012;59:1377–1382.
26.
MatheyDGWendigIBoxbergerM. Treatment of bifurcation lesions with
a drug-eluting balloon: the PEPCAD V (Paclitaxel Eluting PTCA Balloon in
Coronary Artery Disease) trial.
EuroIntervention. 2011;7Suppl K:K61–65.
